Xiaohong Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaohong Xu has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Honglian Zhou
Department of Ultrasound Medicine, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
4 shared publications- Yuping Yang
Department of Ultrasound Medicine, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
4 shared publications Xin Liang
Department of Ultrasound Medicine, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
3 shared publications- Hui-Xiong Xu
Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tenth People's Hospital of Tongji University Shanghai, China
2 shared publications Jun-Mei Xu
Tenth People’s Hospital of Tongji University
2 shared publicationsLe-Hang Guo
Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University School of Medicine, Shanghai 200072, China
2 shared publications
Latest Publications
- Open Access
- 19 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Application of ultrasound combined with microbubbles in conversion therapy for advanced liver cancer
Ultrasound combined with microbubbles (USMB) at a low mechanical index has been shown to enhance blood perfusion and drug delivery, suggesting its potential to augment tumor immunotherapy. This study aims to evaluate whether the addition of USMB to conversion therapy can improve tumor response and local perfusion in patients with advanced hepatocellular carcinoma (HCC), while maintaining a comparable safety profile. This study enrolled 40 patients with unresectable advanced hepatocellular carcinoma (HCC) who underwent conversion therapy, including locoregional interventional therapy, targeted therapy, and immunotherapy. All patients underwent two contrast-enhanced ultrasound (CEUS) examinations after the conversion therapy to assess changes in perfusion. The experimental group (n = 16) received adjuvant ultrasound-mediated microbubble (USMB) treatment in the interval between the two examinations, whereas the control group (n = 24) did not. Following conversion therapy, the maximum diameter of the viable tumor in the combination treatment group \(\:\text{n}\text{=16}\) was significantly smaller than that in the control group \(\:\text{n}\text{=24}\) \(\:\text{P}\text{=0.013}\). Moreover, the reduction rate of the maximum viable tumor diameter was significantly greater in the combination treatment group \(\:\text{P}\text{=0.006}\). Although the combination group demonstrated a higher clinical benefit rate, no statistically significant difference in treatment response according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) was observed between the two groups \(\:\text{P}\text{=0.330}\). In addition, CEUS evaluation showed an increase in the blood flow perfusion index in the combination group following ultrasound treatment. USMB can improve local blood flow perfusion in advanced liver cancer and may enhance the efficacy of conversion therapy without increasing treatment-related adverse effects.- 19 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessApplication of ultrasound combined with microbubbles in conversion therapy for advanced liver cancer
Ultrasound combined with microbubbles (USMB) at a low mechanical index has been shown to enhance blood perfusion and drug delivery, suggesting its potential to augment tumor immunotherapy. This study aims to evaluate whether the addition of USMB to conversion therapy can improve tumor response and local perfusion in patients with advanced hepatocellular carcinoma (HCC), while maintaining a comparable safety profile. This study enrolled 40 patients with unresectable advanced hepatocellular carcinoma (HCC) who underwent conversion therapy, including locoregional interventional therapy, targeted therapy, and immunotherapy. All patients underwent two contrast-enhanced ultrasound (CEUS) examinations after the conversion therapy to assess changes in perfusion. The experimental group (n = 16) received adjuvant ultrasound-mediated microbubble (USMB) treatment in the interval between the two examinations, whereas the control group (n = 24) did not. Following conversion therapy, the maximum diameter of the viable tumor in the combination treatment group \(\:\text{n}\text{=16}\) was significantly smaller than that in the control group \(\:\text{n}\text{=24}\) \(\:\text{P}\text{=0.013}\). Moreover, the reduction rate of the maximum viable tumor diameter was significantly greater in the combination treatment group \(\:\text{P}\text{=0.006}\). Although the combination group demonstrated a higher clinical benefit rate, no statistically significant difference in treatment response according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) was observed between the two groups \(\:\text{P}\text{=0.330}\). In addition, CEUS evaluation showed an increase in the blood flow perfusion index in the combination group following ultrasound treatment. USMB can improve local blood flow perfusion in advanced liver cancer and may enhance the efficacy of conversion therapy without increasing treatment-related adverse effects. - Open Access
- 9 June 2026
- Published by Springer Nature in BMC Medical Imaging
- Vol. 26 (1)
Nomogram prediction model for pathological complete response of metastatic axillary lymph nodes of breast cancer after neoadjuvant chemotherapy
To evaluate the predictive value of a nomogram model combining ultrasound features and clinical indicators for pathological complete response (pCR) of metastatic axillary lymph nodes in breast cancer after neoadjuvant chemotherapy (NACT). A total of 109 women with histologically confirmed breast cancer and axillary lymph node metastasis were retrospectively analyzed. Patients were divided into pCR and non-pCR groups after NACT. A nomogram model was established using univariate and multivariate logistic regression analyses. The predictive performance of the clinical model, ultrasound model, and combined model was compared using the area under the curve (AUC). Molecular subtype, clinical stage, pre-NACT metastatic axillary lymph node subtype, post-NACT reduction rate of lymph node short diameter, and post-NACT reduction rate of primary tumor maximum diameter were independent predictors of axillary lymph node pCR. The combined model (AUC 0.844, 95%CI: 0.773-0.915, P < 0.05) showed significantly improved predictive ability compared with the clinical model (AUC 0.725, 95%CI: 0.628-0.823, P < 0.05) and ultrasound model (AUC 0.754, 95%CI: 0.665-0.844, P < 0.05). The nomogram combining ultrasound and clinical indicators effectively predicts pCR of metastatic axillary lymph nodes after NACT and provides a reference for surgical selection. However, the single‑center design, small sample size, and lack of external and prospective validation limit its generalizability. Multi‑center prospective validation is warranted.
- 9 June 2026
- Published by Springer Nature in BMC Medical Imaging
- Vol. 26 (1)
Open AccessNomogram prediction model for pathological complete response of metastatic axillary lymph nodes of breast cancer after neoadjuvant chemotherapy
To evaluate the predictive value of a nomogram model combining ultrasound features and clinical indicators for pathological complete response (pCR) of metastatic axillary lymph nodes in breast cancer after neoadjuvant chemotherapy (NACT). A total of 109 women with histologically confirmed breast cancer and axillary lymph node metastasis were retrospectively analyzed. Patients were divided into pCR and non-pCR groups after NACT. A nomogram model was established using univariate and multivariate logistic regression analyses. The predictive performance of the clinical model, ultrasound model, and combined model was compared using the area under the curve (AUC). Molecular subtype, clinical stage, pre-NACT metastatic axillary lymph node subtype, post-NACT reduction rate of lymph node short diameter, and post-NACT reduction rate of primary tumor maximum diameter were independent predictors of axillary lymph node pCR. The combined model (AUC 0.844, 95%CI: 0.773-0.915, P < 0.05) showed significantly improved predictive ability compared with the clinical model (AUC 0.725, 95%CI: 0.628-0.823, P < 0.05) and ultrasound model (AUC 0.754, 95%CI: 0.665-0.844, P < 0.05). The nomogram combining ultrasound and clinical indicators effectively predicts pCR of metastatic axillary lymph nodes after NACT and provides a reference for surgical selection. However, the single‑center design, small sample size, and lack of external and prospective validation limit its generalizability. Multi‑center prospective validation is warranted.
- Open Access
- 31 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Predicting pathological complete response to breast cancer neoadjuvant therapy using multi-combination machine learning models based on vision transformer features
The significance of multi-combination machine learning models utilizing vision transformer (VIT) features in forecasting pathological complete response (pCR) after breast cancer neoadjuvant therapy (NAT). A retrospective study was conducted on 124 breast cancer patients who were confirmed by biopsy pathology and underwent surgical resection after NAT to evaluate pCR, and they were divided into a training cohort (n = 87) and a validation cohort (n = 37). Deep learning features were extracted from pre-biopsy ultrasound images based on VIT, ResNet50, and VGG16 convolutional neural network algorithms. Based on the Wilcoxon test, 9, 7, and 7 high-value features were identified from VIT, Resnet50, and VGG16 features, respectively. Using 12 machine learning algorithms, 111, 87, and 82 models were developed utilizing VIT, Resnet50, and VGG16 features. The Stepglm [forward], NaiveBayes, and glmBoost + Ridge ensemble algorithms achieved the highest area under the curve (AUCs). In both the training and validation cohorts, the AUCs of the optimal algorithms were: 0.872 and 0.839 for VIT, 0.837 and 0.804 for Resnet50, and 0.835 and 0.804 for VGG16. The predictive models developed based on VIT features have higher values in evaluating NAT-pCR for breast cancer compared to features quantified by other deep learning algorithms. The application of multi-combination models allows for the selection of the optimal algorithm to achieve higher prediction performance.
- 31 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPredicting pathological complete response to breast cancer neoadjuvant therapy using multi-combination machine learning models based on vision transformer features
The significance of multi-combination machine learning models utilizing vision transformer (VIT) features in forecasting pathological complete response (pCR) after breast cancer neoadjuvant therapy (NAT). A retrospective study was conducted on 124 breast cancer patients who were confirmed by biopsy pathology and underwent surgical resection after NAT to evaluate pCR, and they were divided into a training cohort (n = 87) and a validation cohort (n = 37). Deep learning features were extracted from pre-biopsy ultrasound images based on VIT, ResNet50, and VGG16 convolutional neural network algorithms. Based on the Wilcoxon test, 9, 7, and 7 high-value features were identified from VIT, Resnet50, and VGG16 features, respectively. Using 12 machine learning algorithms, 111, 87, and 82 models were developed utilizing VIT, Resnet50, and VGG16 features. The Stepglm [forward], NaiveBayes, and glmBoost + Ridge ensemble algorithms achieved the highest area under the curve (AUCs). In both the training and validation cohorts, the AUCs of the optimal algorithms were: 0.872 and 0.839 for VIT, 0.837 and 0.804 for Resnet50, and 0.835 and 0.804 for VGG16. The predictive models developed based on VIT features have higher values in evaluating NAT-pCR for breast cancer compared to features quantified by other deep learning algorithms. The application of multi-combination models allows for the selection of the optimal algorithm to achieve higher prediction performance.
- Open Access
- 3 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12) , e98355
Multimodal Ultrasound Manifestations of a Central Intraductal Papilloma at the Nipple and Its Causes of Misdiagnosis: A Case Report
Intraductal papillomas (IPs) are tumors arising from the ductal epithelial cells of the breast. Common symptoms associated with IPs include serous or serosanguineous nipple discharge and palpable masses. We present a case involving a 59-year-old female patient who experienced papillary lesions and nipple discharge for 20 years. Diagnostic imaging for this patient included mammography, conventional ultrasound, and contrast-enhanced ultrasound, which revealed an irregular and poorly defined mass at the right nipple. The ultrasound findings raised the possibility of Paget's disease of the breast, while a biopsy of the right papillary neoplasm confirmed the diagnosis of an IP. The presentation of an IP as a neoplasm is uncommon. This article primarily discusses rare cases and examines multimodal ultrasound manifestations to enhance the predictive accuracy of diagnosing both benign and malignant breast lesions, thereby reducing the rate of misdiagnosis.
- 3 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12) , e98355
Open AccessMultimodal Ultrasound Manifestations of a Central Intraductal Papilloma at the Nipple and Its Causes of Misdiagnosis: A Case Report
Intraductal papillomas (IPs) are tumors arising from the ductal epithelial cells of the breast. Common symptoms associated with IPs include serous or serosanguineous nipple discharge and palpable masses. We present a case involving a 59-year-old female patient who experienced papillary lesions and nipple discharge for 20 years. Diagnostic imaging for this patient included mammography, conventional ultrasound, and contrast-enhanced ultrasound, which revealed an irregular and poorly defined mass at the right nipple. The ultrasound findings raised the possibility of Paget's disease of the breast, while a biopsy of the right papillary neoplasm confirmed the diagnosis of an IP. The presentation of an IP as a neoplasm is uncommon. This article primarily discusses rare cases and examines multimodal ultrasound manifestations to enhance the predictive accuracy of diagnosing both benign and malignant breast lesions, thereby reducing the rate of misdiagnosis.
- 14 October 2025
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (1) , 355-367
Silencing of telomerase RNA component induces autophagy and ferroptosis in A549 and H838 lung cancer cells via AMPK-mediated signaling
Long non-coding RNAs (lncRNAs) are involved in tumorigenesis. The telomerase RNA component (TERC) is a lncRNA that functions as an essential template for the addition of the telomere repeats; its dysfunctions has been associated with various human diseases. However, how dysregulation of TERC expression and activity affects lung adenocarcinoma (LUAD) progression remains elusive. RNA sequencing (RNA-seq) analysis was used to compare the expression levels of TERC in cancerous and adjacent normal lung tissues. Functional assays of TERC in LUAD cell lines were performed by siRNA-mediated knockdown. Cell proliferation was assessed using the water-soluble tetrazolium salt-1 (WST-1) assay, while colony formation capability was evaluated through colony formation assays. Cell migration and invasion were analyzed using Transwell assays. Reactive oxygen species (ROS) levels were determined by flow cytometry and examined by fluorescence microscopy. The morphology of mitochondria was observed using transmission electron microscopy. Protein expression was analyzed by western blot. The formation of autophagosomes was monitored by fluorescence microscopy following the expression of fluorescently tagged LC3. Xenograft experiments were conducted to test the inhibition of TERC knockdown in LUAD proliferation in vivo. RNA-seq analysis showed that the expression of TERC was upregulated in lung cancer tissues. Silencing TERC suppressed the proliferation, migration, and invasion of lung cancer cells in vitro. Additionally, it inhibited the growth of pulmonary xenografts in mice in vivo. Mechanistic analyses indicated that silencing of TERC increased the expression of autophagy-related proteins LC3B, Beclin-1, and AMP-activated protein kinase (AMPK), while the expression of p62 protein and ferroptosis-regulated proteins GPX4 and SLC7A11 were diminished. Importantly, inhibition of AMPK function counterbalanced the effects of TERC knockdown on autophagy and ferroptosis in LUAD cells. These findings reveal that suppression of TERC in lung cancer promotes autophagy and ferroptosis via regulation of AMPK. They help to understand the mechanism underlying TERC activity in tumorigenesis. It will be of interest to determine the clinical significance of TERC dysregulation in lung cancer.
- 14 October 2025
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (1) , 355-367
Silencing of telomerase RNA component induces autophagy and ferroptosis in A549 and H838 lung cancer cells via AMPK-mediated signaling
Long non-coding RNAs (lncRNAs) are involved in tumorigenesis. The telomerase RNA component (TERC) is a lncRNA that functions as an essential template for the addition of the telomere repeats; its dysfunctions has been associated with various human diseases. However, how dysregulation of TERC expression and activity affects lung adenocarcinoma (LUAD) progression remains elusive. RNA sequencing (RNA-seq) analysis was used to compare the expression levels of TERC in cancerous and adjacent normal lung tissues. Functional assays of TERC in LUAD cell lines were performed by siRNA-mediated knockdown. Cell proliferation was assessed using the water-soluble tetrazolium salt-1 (WST-1) assay, while colony formation capability was evaluated through colony formation assays. Cell migration and invasion were analyzed using Transwell assays. Reactive oxygen species (ROS) levels were determined by flow cytometry and examined by fluorescence microscopy. The morphology of mitochondria was observed using transmission electron microscopy. Protein expression was analyzed by western blot. The formation of autophagosomes was monitored by fluorescence microscopy following the expression of fluorescently tagged LC3. Xenograft experiments were conducted to test the inhibition of TERC knockdown in LUAD proliferation in vivo. RNA-seq analysis showed that the expression of TERC was upregulated in lung cancer tissues. Silencing TERC suppressed the proliferation, migration, and invasion of lung cancer cells in vitro. Additionally, it inhibited the growth of pulmonary xenografts in mice in vivo. Mechanistic analyses indicated that silencing of TERC increased the expression of autophagy-related proteins LC3B, Beclin-1, and AMP-activated protein kinase (AMPK), while the expression of p62 protein and ferroptosis-regulated proteins GPX4 and SLC7A11 were diminished. Importantly, inhibition of AMPK function counterbalanced the effects of TERC knockdown on autophagy and ferroptosis in LUAD cells. These findings reveal that suppression of TERC in lung cancer promotes autophagy and ferroptosis via regulation of AMPK. They help to understand the mechanism underlying TERC activity in tumorigenesis. It will be of interest to determine the clinical significance of TERC dysregulation in lung cancer.
- Open Access
- 1 August 2024
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 14 (8) , 5721-5736
Diagnostic efficacy of the contrast-enhanced ultrasound thyroid imaging reporting and data system classification for benign and malignant thyroid nodules
Background: The contrasted-enhanced ultrasound thyroid imaging reporting and data system (CEUS TI-RADS) is the first international risk stratification system for thyroid nodules based on conventional ultrasound (US) and CEUS. This study aimed to evaluate the diagnostic efficacy of CEUS TI-RADS for benign and malignant thyroid nodules and to assess the related interobserver agreement. Methods: The study recruited 433 patients who underwent thyroid US and CEUS between January 2019 and June 2023 at the Affiliated Hospital of Guangdong Medical University. A retrospective analysis of 467 thyroid nodules confirmed by fine-needle aspiration (FNA) and/or surgery was performed. Further, a CEUS TI-RADS classification was assigned to each thyroid nodule based on the CEUS TI-RADS scoring criteria for the US and CEUS features of the nodule. The nodules were grouped based on their sizes as follows: size ≤1 cm, group A; size >1 and ≤4 cm, group B; and size >4 cm, group C. Multivariate logistic regression was used to analyze independent risk factors for malignant thyroid nodules. Pathological assessment was the reference standard for establishing the sensitivity (SEN), specificity (SPE), accuracy (ACC), positive predictive value (PPV), and negative predictive value (NPV) of CEUS TI-RADS in diagnosing malignant thyroid nodules. The area under the curve (AUC) in the receiver operating characteristic (ROC) curve analysis was used to compare the diagnostic efficacy of the scoring system in predicting malignancy in three groups of nodules. The intragroup correlation coefficient (ICC) was adopted to assess the interobserver agreement of the CEUS TI-RADS score. Results: Out of the 467 thyroid nodules, 262 were malignant and 205 were benign. Logistic regression analysis revealed that the independent risk factors for malignant thyroid nodules included punctate echogenic foci (PConclusions: In summary, CEUS TI-RADS demonstrated significant efficacy in distinguishing thyroid nodules. Nonetheless, there were variations in its capacity to detect malignant nodules across diverse sizes, and it demonstrate optimal performance in 1- to 4-cm nodules. These findings may serve as important insights for clinical diagnoses.
- 1 August 2024
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 14 (8) , 5721-5736
Open AccessDiagnostic efficacy of the contrast-enhanced ultrasound thyroid imaging reporting and data system classification for benign and malignant thyroid nodules
Background: The contrasted-enhanced ultrasound thyroid imaging reporting and data system (CEUS TI-RADS) is the first international risk stratification system for thyroid nodules based on conventional ultrasound (US) and CEUS. This study aimed to evaluate the diagnostic efficacy of CEUS TI-RADS for benign and malignant thyroid nodules and to assess the related interobserver agreement. Methods: The study recruited 433 patients who underwent thyroid US and CEUS between January 2019 and June 2023 at the Affiliated Hospital of Guangdong Medical University. A retrospective analysis of 467 thyroid nodules confirmed by fine-needle aspiration (FNA) and/or surgery was performed. Further, a CEUS TI-RADS classification was assigned to each thyroid nodule based on the CEUS TI-RADS scoring criteria for the US and CEUS features of the nodule. The nodules were grouped based on their sizes as follows: size ≤1 cm, group A; size >1 and ≤4 cm, group B; and size >4 cm, group C. Multivariate logistic regression was used to analyze independent risk factors for malignant thyroid nodules. Pathological assessment was the reference standard for establishing the sensitivity (SEN), specificity (SPE), accuracy (ACC), positive predictive value (PPV), and negative predictive value (NPV) of CEUS TI-RADS in diagnosing malignant thyroid nodules. The area under the curve (AUC) in the receiver operating characteristic (ROC) curve analysis was used to compare the diagnostic efficacy of the scoring system in predicting malignancy in three groups of nodules. The intragroup correlation coefficient (ICC) was adopted to assess the interobserver agreement of the CEUS TI-RADS score. Results: Out of the 467 thyroid nodules, 262 were malignant and 205 were benign. Logistic regression analysis revealed that the independent risk factors for malignant thyroid nodules included punctate echogenic foci (PConclusions: In summary, CEUS TI-RADS demonstrated significant efficacy in distinguishing thyroid nodules. Nonetheless, there were variations in its capacity to detect malignant nodules across diverse sizes, and it demonstrate optimal performance in 1- to 4-cm nodules. These findings may serve as important insights for clinical diagnoses.
- 25 July 2024
- Published by SAGE Publications in Clinical Hemorheology and Microcirculation
- Vol. 87 (3) , 367-373
Multimodal ultrasonic manifestations of secretory carcinoma of the breast
Secretory carcinoma of the breast (SCB) is a rare and specific type of breast cancer. Owing to its rarity, the number of SCB reports available is limited, with most of them focusing on clinical and pathological characteristics but no reports on its multimodal ultrasound (US) features. Thus, we present a rare case of SCB, retrospectively analyzing manifestations of US and contrast-enhanced US, as well as its pathological basis, aiming to enhance the understanding of US image features of SCB and provide more valuable information for clinical diagnosis. Moreover, the treatment strategy adopted for this patient may serve as a template for future management of SCB.
- 25 July 2024
- Published by SAGE Publications in Clinical Hemorheology and Microcirculation
- Vol. 87 (3) , 367-373
Multimodal ultrasonic manifestations of secretory carcinoma of the breast
Secretory carcinoma of the breast (SCB) is a rare and specific type of breast cancer. Owing to its rarity, the number of SCB reports available is limited, with most of them focusing on clinical and pathological characteristics but no reports on its multimodal ultrasound (US) features. Thus, we present a rare case of SCB, retrospectively analyzing manifestations of US and contrast-enhanced US, as well as its pathological basis, aiming to enhance the understanding of US image features of SCB and provide more valuable information for clinical diagnosis. Moreover, the treatment strategy adopted for this patient may serve as a template for future management of SCB.
- Open Access
- 13 May 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (1) , 100-106
Comparison of laparoscopic radiofrequency ablation with percutaneous radiofrequency ablation in the treatment of chronic hepatitis B-related hepatocellular carcinoma involving specific sites: A retrospective cohort study
- 13 May 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (1) , 100-106
Open AccessComparison of laparoscopic radiofrequency ablation with percutaneous radiofrequency ablation in the treatment of chronic hepatitis B-related hepatocellular carcinoma involving specific sites: A retrospective cohort study
- Open Access
- 1 January 2023
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 18 (1) , 20220652
Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
The aim of this study is to investigate certain genetic features of intrahepatic cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor tissues from the patients were subjected to next-generation sequencing of a multi-genes panel. Tumor mutation burden (TMB), mutated genes, copy number variants (CNVs), and pathway enrichment analysis were performed. The median TMB was 2.76 Mutation/Mb (range, 0–36.62 Mutation/Mb) in ICCA patients. The top two most commonly mutated genes in ICCA were KRAS (33%) and TP53 (25%). The co-mutations of KRAS and TP53 were 16.7% (2/12) in ICCA patients. Notably, patient P6 with the highest TMB did not have KRAS and TP53 mutations. Additionally, TP53 and/or KRAS alterations were significantly associated with poor progression-free survival than those with wild type (1.4 months vs 18 months). DNA damage repair and homologs recombinant repair deficiencies were significantly associated with high TMB in ICCA cases. In conclusion, we found that certain genetic mutations of TP53 and KRAS could predict poor prognosis in ICCA patients.
- 1 January 2023
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 18 (1) , 20220652
Open AccessGenetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
The aim of this study is to investigate certain genetic features of intrahepatic cholangiocarcinoma (ICCA). A total of 12 eligible ICCA patients were enrolled, and tumor tissues from the patients were subjected to next-generation sequencing of a multi-genes panel. Tumor mutation burden (TMB), mutated genes, copy number variants (CNVs), and pathway enrichment analysis were performed. The median TMB was 2.76 Mutation/Mb (range, 0–36.62 Mutation/Mb) in ICCA patients. The top two most commonly mutated genes in ICCA were KRAS (33%) and TP53 (25%). The co-mutations of KRAS and TP53 were 16.7% (2/12) in ICCA patients. Notably, patient P6 with the highest TMB did not have KRAS and TP53 mutations. Additionally, TP53 and/or KRAS alterations were significantly associated with poor progression-free survival than those with wild type (1.4 months vs 18 months). DNA damage repair and homologs recombinant repair deficiencies were significantly associated with high TMB in ICCA cases. In conclusion, we found that certain genetic mutations of TP53 and KRAS could predict poor prognosis in ICCA patients.